A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects With Early Alzheimer's Disease

Trial Profile

A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects With Early Alzheimer's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs JNJ 54861911 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jul 2016 This trial was completed in Netherlands, according to European Clinical Trials Database.
    • 06 Jul 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top